PRT120 OIT Wins EAACI Prize for Durable Peanut Allergy Remission

New 3-year follow-up data on PRT120 peanut oral immunotherapy show that children who achieved remission remained protected and continued to consume peanuts without daily dosing safely, a finding recognized with a European Academy of Allergy and Clinical Immunology (EACCI) Prize and reinforcing remission as the optimal treatment goal over desensitization.1

Prota Therapeutics received an EACCI Prize for an outstanding oral abstract at the 2025 EAACI Annual Congress, held in Glasgow, United Kingdom, from June 13 – 16, 2025. The presentation shared 3-year post-treatment findings from the phase 2b PPOIT-003 long-term study of PRT120, a peanut oral immunotherapy with a proprietary short-term dosing regimen intended to induce durable remission. The abstract was titled, “Patterns of peanut ingestion in remission vs. desensitized patients after completion of peanut oral immunotherapy at 3 years post-treatment.”

“This recognition from EAACI underscores the clinical importance of remission as an endpoint,” said lead investigator and presenter Paxton Loke, PhD, a research clinician at Murdoch Children’s Research Institute.1 “To see children remain protected and able to eat peanuts freely three years after completing PRT120 treatment, without the anxiety of significant reactions or the demands of indefinite dosing, demonstrates the potential of this approach to transform care for peanut allergy.”

The award signals the significance of remission as a durable and clinically meaningful endpoint. This is not the first time organizations have recognized Prota’s work, either. The company previously received an award at the 2023 GALEN GA2FA Annual Conference for their 2-year follow-up findings.

“While these awards are not formal measures of clinical success, they do reflect meaningful acknowledgment from leading scientific forums,” Professor Mimi Tang, PhD, director of the Allergy Translation Centre and head of Allergy Immunology at MCRI, along with scientific founder of Prota, said in a statement.1 “Importantly, they provide a strong foundation for our upcoming four- to five-year analyses, which continue to show persistence of remission and sustained improvements in quality of life – rare achievements in the food allergy space.”

PRT120 is the first oral immunotherapy developed to induce durable remission of peanut allergy, achieved by modulating immune responses to suppress peanut-specific IgE production. Its dosing regimen involves a rapid build-up followed by high-dose maintenance over 18 months. In a phase 2b trial, PRT120 delivered best-in-class efficacy, with nearly 80% of patients tolerating the equivalent of 20–25 peanuts at treatment completion, and became the first therapy to show sustained protection after treatment discontinuation.2

At the 2-year follow-up, over 95% of children who achieved remission were safely consuming peanuts. By 3 years, more than 90% maintained regular intake without moderate or severe reactions requiring epinephrine. In contrast, participants who were desensitized without remission struggled with regular consumption, experienced greater rates of adverse reactions, and were more likely to discontinue treatment. After 3 years of ad libitum peanut consumption, no moderate or severe reactions occurred among patients in remission (n = 53), whereas 16.7% and 11.1% of desensitized participants reported moderate and severe reactions, respectively, with 6.1% requiring a rescue adrenaline injector.2

These findings, recognized by the EAACI, lay the groundwork for upcoming 4- and 5-year follow-up analyses and the initiation of a phase 3 trial. A phase 3 trial evaluating PRT120 is slated to begin next year in the US.1

“With its differentiated dosing regimen and demonstrated durability of effect, PRT120 has the potential to offer children and families the freedom to live without the daily fear and treatment burden of peanut allergy,” said Guillaume Pfefer, PhD, director of Prota Therapeutics.1

References

1. Prota Therapeutics Announces PRT120 Follow-on Study Awarded EAACI Prize for Long-Term Post-Treatment Data Demonstrating Durable Remission following 18 Months of PRT120 Peanut Oral Immunotherapy. Business Wire. Published September 16, 2025. Accessed September 16, 2025. https://www.businesswire.com/news/home/20250916520078/en/Prota-Therapeutics-Announces-PRT120-Follow-on-Study-Awarded-EAACI-Prize-for-Long-Term-Post-Treatment-Data-Demonstrating-Durable-Remission-Following-18-months-of-PRT120-Peanut-Oral-Immunotherapy

2. Patterns of Peanut Ingestion in Remission Vs Desensitized Patients after Completion of Peanut Oral Immunotherapy at 3-years post-treatment. Y-congress.com. Published 2025. Accessed September 16, 2025. https://eaaci2025.process.y-congress.com/ScientificProcess/Data/67/587/Abstracts/05f13666726ca67f6421b6cc5493a3a0.html